Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics (CCCC)
NASDAQ:CCCC
CCCC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.79 - $11.88
Previous CloseN/A
Volume165.25K
Average Volume (3M)1.82M
Market Cap
$211.06M
Enterprise Value$208.33M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.60
Next Earnings
May 08, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding70,588,960
10 Day Avg. Volume1,617,869
30 Day Avg. Volume1,823,097
Standard Deviation0.42
R-Squared0.11
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.31
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.15
Enterprise Value/Ebitda-2.14
Forecast
1Y Price Target
$21.50Price Target Upside614.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
C4 Therapeutics News
PremiumCompany Announcements
C4 Therapeutics Outlines 2025 Milestones and Achievements
PremiumCompany Announcements
C4 Therapeutics Appoints Steve Hoerter to Board
---
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyC4 Therapeutics presented updated data showing increased activity of cemsidomide as monotherapy in non-Hodgkin's lymphoma.
Partnership PotentialManagement intends to partner cemsi to maximize value, which could result in a rally of shares upon an announcement.
Bears Say
Adverse EventsThere were notable Grade 3 or higher treatment-related adverse events, such as neutropenia and anemia.
---
Ownership Overview
8.89% Insiders
14.31% Mutual Funds
0.34% Other Institutional Investors
66.33% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $2.79 and its highest was $11.88 in the past 12 months.
What is C4 Therapeutics’s market cap?
C4 Therapeutics’s market cap is $211.06M.
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 75 days.
How were C4 Therapeutics’s earnings last quarter?
Currently, no data Available
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -0.49.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 70,588,960 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of C4 Therapeutics?
Currently, no hedge funds are holding shares in CCCC
---
C4 Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (614.29% Upside)
$21.50 (614.29% Upside)
Blogger Sentiment
Neutral
CCCC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 21.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.55%
12-Months-Change
Fundamentals
Return on Equity
-46.00%
Trailing 12-Months
Asset Growth
12.93%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.
---
CCCC Stock 12 Month Forecast
Average Price Target
$21.50
▲(614.29% Upside)
Technical Analysis
Arvinas Holding Company
―
Nurix Therapeutics
―
Kymera Therapeutics
―
Foghorn Therapeutics
―
Monte Rosa Therapeutics
―
Best Analysts Covering CCCC
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-11.07%
reiterated a buy rating 4 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -11.07% per trade.
---